Epiomic Epidemiology Series: Huntington’s DISEASE Forecast in 20 Major Markets 2018–2028

March 2018 | 86 pages | ID: E47E5D732AFEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Huntington’s disease in 20 Major Markets

Huntington’s disease (HD) is a rare hereditary genetic disorder of autosomal dominant nature. It is driven by a mutation in the HTT gene, coding for the protein huntingtin, which involves an abnormally large number of repeated sequences. It is a neurodegenerative disorder with onset at an average age of 40 years, leading to a varied range of motor, cognitive and psychiatric symptoms. The disease affects people in their most productive period of life and constitutes a serious and progressive burden to both the patients and their families.

This report provides the current prevalent population for Huntington’s disease across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of Huntington’s disease patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of Huntington’s disease include:

• Severe psychiatric disturbances (depression, suicidal ideation, psychosis)
• Pneumonia (due to aspiration of food and drink caused by dysphagia)
• Cardiovascular diseases
• Injuries due to falls
• Malnutrition

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global Huntington’s disease market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of Huntington’s disease and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of Huntington’s disease patients.
• Identification of Huntington’s disease patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of Huntington’s disease patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

UHDRS

TOTAL FUNCTIONAL CAPACITY (TFC)

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR HUNTINGTON’S DISEASE

FEATURES OF HUNTINGTON’S DISEASE PATIENTS

COMORBIDITIES OF HUNTINGTON’S DISEASE PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Total Functional Capacity scores and stages
Table 2. Prevalence of Huntington’s disease, total (000s)
Table 3. Prevalence of Huntington’s disease, males (000s)
Table 4. Prevalence of Huntington’s disease, females (000s)
Table 5. Huntington's disease patients by UHRDS motor score, total (000s)
Table 6. Huntington's disease patients by movement disorder phenotype, total (000s)
Table 7. Huntington's disease patients by TFC stage, total (000s)
Table 8. Huntington's disease patients with TFC stage I by grade of striatal atrophy, total (000s)
Table 9. Huntington's disease patients with TFC stage II by grade of striatal atrophy, total (000s)
Table 10. Huntington's disease patients with TFC stage III by grade of striatal atrophy, total (000s)
Table 11. Huntington's disease patients with TFC stage IV by grade of striatal atrophy, total (000s)
Table 12. Huntington's disease patients with autonomic nervous system dysfunction, total (000s)
Table 13. Huntington's disease patients with psychiatric disorder, total (000s)
Table 14. Huntington's disease patients with cognitive disorder, total (000s)
Table 15. Huntington's disease patients with any mood disorder, total (000s)
Table 16. Huntington's disease patients with any mood disorder by type, total (000s)
Table 17. Huntington's disease patients with personality change, total (000s)
Table 18. Huntington's disease patients with any anxiety disorder, total (000s)
Table 19. Huntington's disease patients with a score of 100 on IS rating, total (000s)
Table 20. Huntington's disease patients by sleep disturbance, total (000s)
Table 21. Abbreviations and acronyms used in the report
Table 22. USA prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 23. USA prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 24. Canada prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 25. Canada prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 26. France prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 27. France prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 28. Germany prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 29. Germany prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 30. Italy prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 31. Italy prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 32. Spain prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 33. Spain prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 34. UK prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 35. UK prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 36. Poland prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 37. Poland prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 38. Netherlands prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 39. Netherlands prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 40. Ireland prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 41. Ireland prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 42. Russia prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 43. Russia prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 44. Turkey prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 45. Turkey prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 46. Japan prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 47. Japan prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 48. China prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 49. China prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 50. South Korea prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 51. South Korea prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 52. India prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 53. India prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 54. Australia prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 55. Australia prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 56. Brazil prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 57. Brazil prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 58. Mexico prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 59. Mexico prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Table 60. Argentina prevalence of Huntington’s disease by 5-yr age cohort, males (000s)
Table 61. Argentina prevalence of Huntington’s disease by 5-yr age cohort, females (000s)
Figure 1. Distribution of age at onset of Huntington’s disease symptoms
Figure 2. Average duration of Huntington's disease by age at onset